---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-019"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ESK-001-019. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 12 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/esk-001-019"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-019

<a id="heading-3.1.9"></a>

## 3.1.9 ESK-001-019

<a id="heading-3.1.9.1"></a>

### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

#### Brief summary in the ClinicalTrials.gov record

> “This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.2"></a>

### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2024-06-21”
> “Primary Completion (Actual) 2024-08-31”
> “Study Completion (Actual) 2024-08-31”
> “First Submitted 2025-12-10”
> “First Posted 2026-01-30”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.2-2"></a>

#### Site in Daytona Beach, Florida, in the ClinicalTrials.gov record

> “This study has 1 location”
> “Daytona Beach, Florida, United States, 32117”
> “Fortrea CRU”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.2-3"></a>

#### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-01-30” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.3"></a>

### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

#### Official title and design details in the ClinicalTrials.gov record

> “A Phase 1, Partially Blinded, Randomized, Crossover Study to Evaluate the Pharmacokinetics and QT/QTc Interval of ESK-001 Compared to Placebo and Moxifloxacin in Healthy Subjects”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-019” |
| Conditions | “Healthy Volunteer” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.3-2"></a>

#### Four treatment sequences, blinding, and central electrocardiogram reading

> “Masking Description: All subjects will be randomized to 1 of 4 treatment sequences; each subject will receive all 4 treatments. Treatments 1 through 3 will be blinded; Treatment 4 will be given open label. The central ECG laboratory will be blinded to treatment assignment”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.4"></a>

### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Age and body size | “Healthy male and female subjects aged between 18 and 55 years, inclusive. Body mass index between ≥18.0 and ≤32.0 kg/m2, inclusive, and a minimum body weight of 45 kg.” |
| Consent | “Able to comprehend and willing to sign an ICF and to abide by the study restrictions.” |
| Health status | “In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations, and from the physical examination at screening or check-in, as assessed by the investigator (or designee).” |
| Electrolytes | “Serum sodium, potassium, calcium, and magnesium levels are within the normal range at screening and check-in-” |
| Ages eligible for study | “18 Years to 55 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Viral infection | “Positive hepatitis panel and/or positive human immunodeficiency virus test, hepatitis B surface antigen, or hepatitis C antibodies.” |
| Liver enzymes | “Alanine aminotransferase or aspartate aminotransferase >1.5 times the upper limit of normal, at screening or check-in.” |
| Hypersensitivity | “History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).” |
| Recent surgery | “Surgery within the past three months prior to the first study drug administration determined by the principal investigator to be clinically relevant.” |
| Gastrointestinal surgery | “History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).” |
| Gilbert's syndrome or cholecystectomy | “History of Gilbert's syndrome or cholecystectomy surgery.” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.5"></a>

### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: Treatment 1: (Therapeutic dose)” | “1 oral dose of ESK-001” |
| “Experimental: Treatment 2: (Supratherapeutic dose)” | “1 oral dose of ESK-001” |
| “Placebo Comparator: Treatment 3: ESK-001-matched placebo” | “ESK-001-matched placebo” |
| “Active Comparator: Treatment 4: (positive control)” | “Moxifloxacin 400 mg tablet” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.6"></a>

### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

#### 3.1.9.6.1 Rationale for Using Placebo-adjusted Change in QTcF as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Change from baseline in placebo-adjusted QTcF (∆∆QTcF)” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter ΔHR” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter Δ PR interval” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter ΔQRS duration” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter ΔQTc interval” | “24 hours” |
| Secondary | “Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation” | “Up to 22 Days” |
| Secondary | “Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations” | “Up to 22 Days” |
| Secondary | “Composite of pharmacokinetic (PK) parameter Vz/F for ESK-001 and metabolites” | “24 hours” |
| Secondary | “Composite of pharmacokinetic (PK) parameter Cmax for ESK-001 and metabolites” | “24 hours” |
| Secondary | “Composite of pharmacokinetic (PK) parameter tmax for ESK-001 and metabolites” | “24 hours” |
| Secondary | “Composite of pharmacokinetic (PK) parameter CL/F for ESK-001 and metabolites” | “24 hours” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.7"></a>

### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

#### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 52”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.7.2"></a>

#### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

#### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

#### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

#### 3.1.9.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.9.8.4"></a>

#### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

#### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

#### Summary

- The study is known only from its ClinicalTrials.gov record, which reads “No Results Posted”; the report holds no QTcF, ECG, pharmacokinetic, or safety result.
- The record was first submitted on 2025-12-10, after the actual study completion date of 2024-08-31.
- The record describes the therapeutic and supratherapeutic arms each as one oral dose of ESK-001 without stating the dose.
- The study gave single doses to 52 healthy participants aged 18 to 55 years at one site, with the moxifloxacin positive control given open label.

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
